Equity Overview
Price & Market Data
Price: $1.90
Daily Change: $0.00 / 0.00%
Daily Range: $1.57 - $1.92
Market Cap: $572,340,480
Daily Volume: 1,352,041
Performance Metrics
1 Week: 7.34%
1 Month: -22.76%
3 Months: -15.18%
6 Months: -26.92%
1 Year: 126.3%
YTD: -15.18%
Company Details
Employees: 231
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.